Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Agilent Technologies    A

AGILENT TECHNOLOGIES

(A)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Agilent Technologies : Makes Immunotherapy Bet With $1.17 Billion Biotek Deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 08:52am EDT

Deal boosts Agilent's offerings in hot area of cancer research.

Life-science tools makers teaming up amid innovation race

Agilent Technologies Inc. agreed to buy closely held BioTek Instruments Inc. for $1.17 billion, in a deal designed to capitalize on a push by big pharmaceutical companies to develop new drugs that harness the immune system to fight cancer.

Santa Clara, Calif.-based Agilent makes instruments and software and provides services to drugmakers in the process of developing new therapies. BioTek, based in Winooski, Vt., focuses on cell-imaging systems that allow companies to see how therapies work in real time.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AGILENT TECHNOLOGIES
07/12AGILENT TECHNOLOGIES : BioTek to be sold for $1.165 billion
AQ
07/12AGILENT TECHNOLOGIES : Makes Immunotherapy Bet With $1.17 Billion Biotek Deal
AQ
07/11AGILENT TECHNOLOGIES : 285.7 kb
PU
07/11AGILENT TECHNOLOGIES : to Acquire BioTek Instruments for $1.17 Billion
DJ
07/11AGILENT TECHNOLOGIES : to Acquire BioTek, Strengthening Leadership Position in G..
BU
07/01AGILENT TECHNOLOGIES : Ex-dividend day for
FA
06/24AGILENT TECHNOLOGIES : Introduces Breakthrough Flow Cytometer
BU
06/19AGILENT TECHNOLOGIES : New State-of-the-Art Facility Increases Agilent's Capacit..
AQ
06/18AGILENT TECHNOLOGIES : New State-of-the-Art Facility Increases Agilent's Capacit..
PU
06/18AGILENT TECHNOLOGIES : New State of the Art Facility Increases Agilent's Capacit..
BU
More news
Financials (USD)
Sales 2019 5 106 M
EBIT 2019 1 151 M
Net income 2019 1 119 M
Finance 2019 317 M
Yield 2019 0,96%
P/E ratio 2019 19,5x
P/E ratio 2020 22,5x
EV / Sales2019 4,19x
EV / Sales2020 3,86x
Capitalization 21 709 M
Chart AGILENT TECHNOLOGIES
Duration : Period :
Agilent Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGILENT TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 81,69  $
Last Close Price 68,70  $
Spread / Highest target 31,0%
Spread / Average Target 18,9%
Spread / Lowest Target -3,93%
EPS Revisions
Managers
NameTitle
Michael R. McMullen President, Chief Executive Officer & Director
Boon Hwee Koh Non-Executive Chairman
Kristin Giffin Vice President-Operations, Quality & Support
Robert W. McMahon Chief Financial Officer & Senior Vice President
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AGILENT TECHNOLOGIES1.84%21 709
THERMO FISHER SCIENTIFIC31.25%117 486
DANAHER CORPORATION38.67%102 584
INTUITIVE SURGICAL10.42%61 953
BOSTON SCIENTIFIC CORPORATION20.66%59 297
ILLUMINA-2.24%43 887